摘要
目的探讨免疫荧光标记的方法测定脑钠肽对心力衰竭诊断的临床应用价值。方法设心衰组97例及对照组50例,利用荧光免疫法测定血浆脑钠肽,并进行心功能分级及标准化心衰评分,对心衰组与对照组、心衰组治疗前后实验数据,进行统计学处理比较分析。结果心衰组血浆脑钠肽为(874.3±853.5)ng/L;非心衰组脑钠肽(20.4±8.7)ng/L,非心衰组明显低于心衰组(P<0.01)。心衰患者经过抗心衰治疗后,血浆脑钠肽浓度下降至(328.8±336.2)ng/L,P<0.01,具统计学意义。治疗后NYHA心功能分级及标准化心衰评分均显著降低,P<0.01,具统计学差异。结论快速床旁检测脑钠肽测定在心衰诊断、心衰严重程度判断、治疗效果及预后判断中具有较高的应用价值,值得推广。
Objective To investigate the clinical value of plasma brain natriuretic peptide （BNP） by immunofluorescence assay in the diagnosis of cardiac heart failure（CHF）. Methods There were two groups,including the control （50） and the trial（97 ）. The plasma BNP concentration was measured with immunofluorescence assay. Then the standardized grades of CHF and the cardiac function class of NYHA were assessed. The statistic methods were employed to analyze the experimental data, such as comparing the data between the control and the trial, the data gained before and after the remedy in the CHF group. Results The plasma BNP average concentration of the trial was （874.3±853.5） ng/L, while that of the control was （20.4±8.7） ng/L. The plasma BNP average concentration of the control was significantly lower than that of the trial（ P 〈 0.01 ）. The plasma BNP concentration in the patients with CHF decreased much more （328.8±336.2ng/L） after the regular pharmacotherapy. The cardiac function class of NYHA and the standardized grade of CHF were all much lower after the remedy （P 〈 0.01 ）. Conclusion BNP assay has significant value in the diagnosis, the judgement of therapeutic effect and the prognosis of the patients with CHF,and is worthy to spread clinical application.
出处
《云南医药》
CAS
2008年第2期119-121,共3页
Medicine and Pharmacy of Yunnan
关键词
脑钠肽
荧光免疫法测定
心力衰竭
Brain natriuretic peptide
Immunofluorescence assay
Cardiac heart failure
